- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Endocyte Inc.
PANEL: Life sciences will see radically different future
May 17, 2013
IBJ convened a panel of experts at its Life Sciences Power Breakfast on May 10 to talk about the industry issues
of venture capital, digital health innovations and research university entrepreneurship.
MorePanel members included Kristin Eilenberg, CEO, Lodestone Logic, Infuse Accelerator; Philip S. Low, Purdue University professor of chemistry, founder and chief science officer at Endocyte Inc. and On Target Laboratories LLC; R. Matthew Neff, president, CHV Capital Inc.; Brian Stemme, project director; BioCrossroads; Brian S. Williams, director, Global Healthcare Strategy, PricewaterhouseCoopers International Ltd.; and Raul Zaveleta, CEO, Indigo BioSystems Inc.
The following is an unedited transcript of the discussion.
Q&A
March 11, 2013
J.K. WallMike Sherman, the chief financial officer at West Lafayette-based Endocyte Inc., talked about how the drug
firm’s funding partnership with New Jersey-based Merck & Co. Inc. has helped accelerate development of the company’s
pipeline, which is branching out into drugs to treat cancers of the lung, prostate and breast.
MoreEndocyte stock sinks due to possible drug-filing delay
February 26, 2013
J.K. WallEndocyte Inc. saw its shares fall nearly 7 percent Tuesday morning after the drug development firm announced that its application
for U.S. approval of a cancer drug could be delayed another 10 months.
MorePROXY CORNER: Endocyte Inc.
May 12, 2012
West Lafayette-based Endocyte Inc. is a biopharmaceutical company developing therapies for the treatment of cancer and inflammatory
diseases.
MoreEndocyte pulls trigger on European drug submission
March 13, 2012
J.K. WallEndocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after
the European Commission granted it orphan drug status.
MoreEndocyte stays course despite being battered by investors
December 31, 2011
J.K. WallAfter spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West
Lafayette-based drug developer is in better position than ever.
MoreCancer-drug firm Endocyte to build commercial team in Indianapolis
November 12, 2011
J.K. WallEndocyte employs 12 people in Indianapolis and plans to add three or four more commercial executives there over the next year
and a half as it anticipates approval of its ovarian cancer medication in Europe.
MoreDrug shortages hit Lilly, Endocyte
November 7, 2011
J.K. WallThe nation’s shortage of certain drugs is threatening to affect research trials being conducted by Eli Lilly and Co.
and Endocyte Inc.
MoreEndocyte's potential enthralls investors
May 7, 2011
Chris O'MalleyShares of Endocyte Inc. have doubled since the company’s initial public offering in February—even though the common
wisdom is it won’t see sales from its first cancer drug until 2014.
MorePROXY CORNER: Endocyte Inc.
April 30, 2011
IBJ StaffWest Lafayette-based Endocyte Inc. is a biopharmaceutical company developing therapies for the treatment of cancer and inflammatory
diseases.
MoreRepeated price cuts take glow off Endocyte IPO
February 12, 2011
Greg AndrewsNew investors got in for $6 a share—which is less than the average price paid by prior investors, a regulatory filing
reveals.
MoreEndocyte prices IPO stock
January 14, 2011
J.K. WallThe West Lafayette-based drug development firm intends to sell 6.15 million shares for $13 to $15 apiece. That would fetch
$80 million to $92 million.
MoreEndocyte's $86M IPO plan a boon for Indiana, investors
August 28, 2010
Greg AndrewsVenture capitalists in Indiana and nationally have thrown money at the company with abandon. Local investors include CID Capital,
Clarian Health Ventures and the Indiana Future Fund.
MoreCancer drug developer Endocyte files for IPO
August 18, 2010
Scott OlsonThe company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet
to be determined.
MoreHealth care venture capital swoons in Indy, holds steady statewide
February 6, 2010
IBJ StaffThe uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009.
MoreEndocyte, Purdue develop prostate cancer treatment device
July 13, 2009
IBJ StaffPurdue University researcher Philip Low, also the chief science officer for West Lafayette-based Endocyte Inc., has developed
a prostate cancer “homing device” to help anti-cancer agents specifically target prostate
cancer tumors.
MoreSponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Ameriana Bank took over Westfield Farmers Market for 2013 and it is held in their parking lot, corner of 32 and Carey road, 5 to 8. I am selling soap and candles there. great market!
B&T certainly has enough of our taxpayer dollars to do this thanks to Mayor Ballard. Given the firm's exceedingly poor reputation in the legal community, the basement would seem a better option.
Should read MAY hire 20 people.
Not a good location for a 300,000 home. 10th Street fumes, buses, noise. Max for this location 150,000.
The state constitution also does not say that the majority has a right to quorum, nor that the minority is required to allow them quorum. In fact, denial of quorum has been a parliamentary maneuver since the establishment of the first parliaments in the early 1600s. The right to deny quorum (and the requirement fore quorum) are to prevent exactly what happened in Indiana: A tyrannical majority pushing through odious, objectionable legislation. Denial of quorum is totally legitimate, and lest we forget, a tactic the GOP has employed many, many times to ensure their issues weren't given short shrift. By allowing the majority to impose "fines" on the minority for exercising the authority the constitution grants them (to deny quorum,) they are violating the constitution.